Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Triulzi, Tiziana"'
Autor:
Triulzi, Tiziana1, Casalini, Patrizia1, Sandri, Marco1, Ratti, Manuela1, Carcangiu, Maria L.2, Colombo, Mario P.3, Balsari, Andrea4, Ménard, Sylvie1, Orlandi, Rosaria1, Tagliabue, Elda1 elda.tagliabue@istitutotumori.mi.it
Publikováno v:
PLoS ONE. Feb2013, Vol. 8 Issue 2, p1-10. 10p.
Autor:
Uva Valentina, Tagliabue Elda, Balsari Andrea, Cataldo Alessandra, Casalini Patrizia, Triulzi Tiziana, Sfondrini Lucia
Publikováno v:
Frontiers in Immunology. 4
Autor:
Balsari Andrea, Mariani Gabriella, Tagliabue Elda, Casalini Patrizia, Varchetta Stefania, Triulzi Tiziana, Bianchi Giulia, Sasso Marianna, Regondi Viola, Sfondrini Lucia
Publikováno v:
Frontiers in Immunology. 4
Autor:
Viola Regondi, Stefania Arioli, Elda Tagliabue, Arianna Bonizzi, Francesca Bianchi, Beatrice Belmonte, Alessia Bertolotti, Claudio Tripodo, Andrea Balsari, Elena Fasano, Tiziana Triulzi, Loris De Cecco, Fabio Corsi, Martina Di Modica, Simone Guglielmetti, Giorgio Gargari, Laura Villani
Publikováno v:
Cancer research. 81(8)
Emerging evidence indicates that gut microbiota affect the response to anticancer therapies by modulating the host immune system. In this study, we investigated the impact of gut microbiota on immune-mediated trastuzumab antitumor efficacy in preclin
Autor:
Anna Ianza, Tiziana Triulzi, Eva Ciruelos, Manuela Milani, Alfredo Molteni, Fabiola Giudici, Maria Rosaria Cappelletti, Silvia Paola Corona, Francesco Schettini, Carla Strina, Navid Sobhani, Guy Jerusalem, Sherine Loi, Stephen B. Fox, Daniele Generali, Ottavia Bernocchi, Maria Chiara Lazzari, Marianna Sirico
Publikováno v:
Breast Cancer Research and Treatment
Purpose mTOR inhibitor everolimus is used for hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer (mBC). No reliable predictive biomarker of response is available. Following evidences from other solid tumors, we aimed to assess the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19e00b9b8ddae4330d6b3c438c58eedc
https://link.springer.com/article/10.1007/s10549-020-05856-3
https://link.springer.com/article/10.1007/s10549-020-05856-3
Autor:
Laura Botti, Maria Teresa Majorini, Claudio Tripodo, Alice Rigoni, Mario P. Colombo, Valeria Cancila, Claudia Chiodoni, Loris De Cecco, Daniele Lecis, Enrico Fontanella, Elena Jachetti, Matteo Dugo, Tiziana Triulzi, Elda Tagliabue
Tumor growth and development is determined by both cancer cell–autonomous and microenvironmental mechanisms, including the contribution of infiltrating immune cells. Because the role of mast cells (MC) in this process is poorly characterized and ev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5961be16be787af28bb8b55bc9f2933
http://hdl.handle.net/10447/414607
http://hdl.handle.net/10447/414607
Autor:
Maria Rosa Cappelletti, Elda Tagliabue, Loris De Cecco, Martina Di Modica, Tiziana Triulzi, Daniele Generali, Serena Di Cosimo, Biagio Paolini, Pier Luigi Lollini, Viola Regondi, Lucia Sfondrini
Publikováno v:
British Journal of Cancer
Background: Optimising the selection of HER2-targeted regimens by identifying subsets of HER2-positive breast cancer (BC) patients who need more or less therapy remains challenging. We analysed BC samples before and after treatment with 1 cycle of tr
Autor:
Silvana Canevari, Andrea Balsari, Sylvie Ménard, Serena Di Cosimo, Marta Giussani, Aleix Prat, Marialuisa L. Carcangiu, Manuela Campiglio, Daniele Generali, Biagio Paolini, Elda Tagliabue, Loris De Cecco, Alberto Bottini, Tiziana Triulzi, Marco Sandri
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
Recercat. Dipósit de la Recerca de Catalunya
instname
Oncotarget
Universidad de Barcelona
Recercat. Dipósit de la Recerca de Catalunya
instname
Oncotarget
While results thus far demonstrate the clinical benefit of trastuzumab, some patients do not respond to this therapy. To identify a molecular predictor of trastuzumab benefit, we conducted whole-transcriptome analysis of primary HER2+ breast carcinom
Autor:
Daniele Generali, Tiziana Triulzi, Giulia Bianchi, Gabriella Mariani, Andrea Balsari, Viola Regondi, Elda Tagliabue, Barbara Oliviero, Martina Di Modica, Stefania Varchetta, Lucia Sfondrini
Publikováno v:
Scopus-Elsevier
Oncotarget
Oncotarget
Recent clinical data indicate a synergistic therapeutic effect between trastuzumab and taxanes in neoadjuvantly treated HER2-positive breast cancer (BC) patients. In HER2+ BC experimental models and patients, we investigated whether this synergy depe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c43dc35ae941efe5eae0d489f8df08b1
http://www.scopus.com/inward/record.url?eid=2-s2.0-84995511494&partnerID=MN8TOARS
http://www.scopus.com/inward/record.url?eid=2-s2.0-84995511494&partnerID=MN8TOARS